Evidence map›Paper›PMID 31895471›Full record

ArticleBritish journal of pharmacology2020

Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD

Zhixuan Wu, Duraippandi Palanimuthu, Nady Braidy, Nor Hawani Salikin, Suhelen Egan, Michael L H Huang, Des R Richardson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Iron Metabolism in Aging and Age-Related Diseases.International journal of molecular sciences · 2022
    Review
  5. TridentateFrontiers in neurology · 2022
    Article
  6. Review
  7. UVA-Triggered Drug Release and Photo-Protection of Skin.Frontiers in cell and developmental biology · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Zhixuan WuMolecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, Australia.
Duraippandi PalanimuthuMolecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, Australia.
Nady BraidyCentre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia.
Nor Hawani SalikinSchool of Biological, Earth and Environmental Sciences, Centre for Marine Science and Innovation, University of New South Wales, Sydney, Australia.
Suhelen EganSchool of Biological, Earth and Environmental Sciences, Centre for Marine Science and Innovation, University of New South Wales, Sydney, Australia.
Michael L H HuangMolecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, Australia.
Des R RichardsonMolecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, Australia.
Robert Bosch (Australia) · AUEnvironmental Earth Sciences · AUHuzhou Central Hospital · CNUniversity of Sydney · AUUNSW Sydney · AU

Funding

Australian Research Council DE170100628Judith Jane Mason and Harold Stannett Williams Memorial FoundationNational Health and Medical Research Council 1021607National Health and Medical Research Council 1062607National Health and Medical Research Council (NHMRC) Australia 1021607NHMRC Senior Principal Research Fellowship 1062607Sydney Medical School for an Early Career Research
6 · The paper itself

Abstract

background and purposeAlzheimer's disease (AD) is a multifactorial condition leading to cognitive decline and represents a major global health challenge in ageing populations. The lack of effective AD therapeutics led us to develop multifunctional nicotinoyl hydrazones to target several pathological characteristics of AD. EXPERIMENTAL APPROACH: We synthesised 20 novel multifunctional agents based on the nicotinoyl hydrazone scaffold, which acts as a metal chelator and a lipophilic delivery vehicle, donating a NAD KEY

resultsThe most promising compound, 6-methoxysalicylaldehyde nicotinoyl hydrazone (SNH6), demonstrated low cytotoxicity, potent iron (Fe)-chelation efficacy, significant inhibition of copper-mediated Aβ aggregation, oxidative stress alleviation, effective donation of NAD CONCLUSIONS AND IMPLICATIONS: The nicotinoyl hydrazones, particularly SNH6, have the potential to act as multifunctional therapeutic agents and delivery vehicles for NAD

Indexed as

Alzheimer DiseaseHydrazonesAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAnimalsAspartic Acid EndopeptidasesCaenorhabditis elegansHumansIron Chelating AgentsNADAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesHydrazonesIron Chelating AgentsNAD

Identifiers

PMID31895471
PMCPMC7161547
OpenAlexW2996983724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.